Prevention of post coital cystitis: the role of D-mannose. Case report

Lower Urinary Tract ◽

Reproductive Age ◽

Women Of Reproductive Age ◽

Tract Infections ◽

Recurrent Cystitis ◽

Recurrent lower urinary tract infections are common among women. One of the important factors of their genesis is sexual activity: there is a positive correlation between sexual intercourse frequency and recurrences of lower urinary tract infections. Post coital cystitis accounts for 30–40% of all chronic recurrent cystitis and occurs in about 25–30% of women of reproductive age. One of the methods for the prevention of post coital cystitis is the use of D-mannose, the effectiveness of which was demonstrated with a clinical example.

Potential Role of Fosfomycin in the Treatment of Community-Acquired Lower Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli

American Journal of Therapeutics ◽

10.1097/mjt.0b013e3182204d60 ◽

2013 ◽

Vol 20 (6) ◽

pp. 685-690 ◽

Cited By ~ 5

Author(s):

Dustin T. Wilson ◽

D. Byron May

Keyword(s):

Escherichia Coli ◽

Urinary Tract ◽

Lower Urinary Tract ◽

Potential Role ◽

Extended Spectrum ◽

Tract Infections ◽

The role of viral infection in the development of recurrent lower urinary tract infections

Urologiia ◽

10.18565/urology.2019.5.136-139 ◽

2019 ◽

Vol 5_2019 ◽

pp. 136-139 ◽

Cited By ~ 1

Author(s):

K.S. Ibishev Ibishev ◽

T.O. Lapteva Lapteva ◽

D.V. Krachotkin Krachotkin ◽

N.N. Ryabenchenko Ryabenchenko ◽

Keyword(s):

Urinary Tract ◽

Viral Infection ◽

Lower Urinary Tract ◽

Tract Infections ◽

Recurrent cystitis and bacterial vaginosis: how to avoid polypharmacy

GYNECOLOGY ◽

10.26442/20795696.2020.4.200275 ◽

2020 ◽

Vol 22 (4) ◽

pp. 17-21

Author(s):

Ekaterina V. Kulchavenya ◽

Aleksandr A. Breusoff

Keyword(s):

Urinary Tract ◽

Bacterial Vaginosis ◽

Lower Urinary Tract ◽

Vaginal Microbiota ◽

Vaginal Candidiasis ◽

Excellent Outcome ◽

Tract Infections ◽

Recurrent Cystitis ◽

Background. The structure of lower urinary tract infections has clear sex-based differences. The vaginal microbiota is a key factor in the pathogenesis of lower urinary tract infections: aerobic vaginitis predisposes to infection and increases the incidence of cystitis by 2.9 times. Aim. To determine the effectiveness of Nifuratel as monotherapy in patients with chronic cystitis and concomitant bacterial vaginosis (BV). Materials and methods. Study design: an open-label, non-comparative, pilot, single-center, prospective study, which included 23 patients with recurrent cystitis and BV. All women received monotherapy with Nifuratel (Macmiror manufactured by Doppel Farmaceutici S.r.l., Italy) in tablets of 200 mg 3 times a day for 7 days. Control visits were performed in 7.90 and 180 days. Results. BV was diagnosed in all patients; 19 (82.6%) women also had vaginal candidiasis. At the end of therapy, 17 (73.9%) patients showed an excellent outcome, 4 (17.4%) a significant improvement, 2 (8.7%) no effect. After the end of three-month therapy, 18 (81.8%) out of 22 patients who left in the study had no complaints of urinary disorders or vaginal discharge. Their urinalyses were normal. Molecular genetic analysis of the vaginal biocenosis showed moderate dysbiosis; Candida spp. was revealed only in 3 (13.6%) cases. 18 patients came for the 4th visit. Within six months after the end of monotherapy with Nifuratel, the patients had no complaints. They all achieved the recovery of vaginal normocenosis with a sufficient amount of Lactobacillus spp. Conclusion. Monotherapy in patients with recurrent cystitis and BV is highly effective for both diseases: 73.9% of women achieved stable normalization of urine and vaginal microbiota analyzes, removal of bacteriuria. The bi-directional action of Nifuratel allows to avoid polypharmacy in this category of patients.